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SARPAM programme, including a regional procurement cooperation intervention
of ARVs, is both a cost beneficial and cost effective way of improving access to
essential medicines in SADC. Specifically, this will have a significant impact on the
access to healthcare of HIV AIDS patients where antiretroviral drug costs will be
significantly reduced.
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OBJECTIVES: Influenza vaccination programs targeted at children have gained in-
creasing attention in recent years. In the US, recommendations for influenza vac-
cination have expanded over the last decade to include all children aged 6 months
to 18 years. However, in most other developed countries childhood influenza vac-
cination has been restricted to targeted programs for children at risk of influenza
complications. METHODS: A literature search was conducted for English-language
economic evaluations of influenza vaccination in those aged less than 18 years.
Studies evaluating vaccination options exclusively targeted at specific risk groups
were excluded. The literature search identified 20 relevant studies which were
reviewed. RESULTS: The studies differed widely in terms of the costs and benefits
that were included. All but one of the studies were conducted from a societal
perspective. The majority of the studies included the value of lost productivity due
to caregivers missing work to care for sick children. However, other forms of lost
productivity were considered by some studies, including those resulting from be-
ing vaccinated, school absenteeism, premature death, and illness in caregivers.
Only a small minority of studies also measured benefits in terms of non-monetised
utilities such as quality-adjusted life years. Several evaluations, particularly those
directly targeted at healthy children, did not include serious influenza complica-
tions. Only one of the reviewed studies used a dynamic transmission model able to
fully incorporate the indirect herd protection to the wider population.
CONCLUSIONS: The conclusions of the studies were generally favourable towards
vaccination. Methodological decisions in terms of what costs and benefits to in-
clude appeared influential. Many studies applied a wider perspective (i.e. including
productivity losses) than the reference case for economic evaluations used in many
countries.
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OBJECTIVES: To calculate the cost of Human Immunodeficiency Virus (HIV) pa-
tients treated with Anti-Retroviral therapy (ARV) including medications, hospital-
izations, tests, and specialist visits over a 12 months follow-up period, 3 Italian
Local Health Units databases were analysed. METHODS: All records (patients 18
years) between January 1, 2008 and December 31, 2009 associated with nucleoside
analogue reverse-transcriptase inhibitor (NRTI), non-nucleoside analogue reverse-
transcriptase inhibitor (NNRTI), protease inhibitor (PI), or other drugs in ATC J05A
group, were included. Data and costs were collected for medications, hospitaliza-
tions, diagnostic tests, and specialist visits for the 12 months after the first ARV
prescription (follow-up). Records of treatment for the 24 month prior to the first
ARV prescription were classified as naïve or experienced. Costs-per-unit for re-
source use were collected from DRGs, National Tariffs and Drugs Formulary.
RESULTS: A total of 779 records were analyzed 515 male (46.49.7years) and 264
female (42.09.2years). Records were classified as naïve (12,7%) and experienced
(87,3%). The most prescribed regimens were EfavirenzTenofovir/Emtricitabine
(TDF/FTC) (22.1%), Atazanavirritonavir(r) TDF/FTC (17.2%), and Lopinavir/
rTDF/FTC (11.2%). No switching of therapy during the follow-up was found in
78.2% of the records. Amid non-switcher records, the annual average total cost
(medications, hospitalizations, tests, and specialist visits) was €9,103.825,302.11,
including €7,099.70 for ARV therapy (77%), €631.65 for HIV-related hospitalizations
(7%), and €551.49 for HIV-related diagnostic tests/specialist visits (6%). Total costs
for EfavirenzTDF/FTC, AtazanavirrTDF/FTC and Lopinavir/rTDF/FTC regi-
mens amounted to 7,637.40€, 11,257.00€ and 9,426.94€ respectively, with higher
total costs being associated with AtazanavirrTDF/FTC. CONCLUSIONS: In this
administrative databases analysis, the annual total average cost of HIV patients
was significantly influenced by specific ARV medications, suggesting that total cost
of therapies could differ significantly from drug acquisition cost of a single drug. A
payer’s perspective should include all direct costs and not only drug acquisition
costs.
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OBJECTIVES: Several health-economics models have evaluated cost-effectiveness
of HPV vaccination in Germany. These static models do not consider the dynamics
of infection or the herd immunity effect of vaccination on vaccinees’ contacts. The
objective of this study is to assess the epidemiological and economic impact of a
prophylactic quadrivalent human papillomavirus vaccine (HPV6/11/16/18) in Ger-
many with the help of a dynamic transmission model. METHODS: We adapted a
previously published HPV6/11/16/18 dynamic transmission model to the German
context. The model was populated with German-specific data where available and
was manually calibrated to fit German epidemiological data. The base case analysis
evaluated the current HPV vaccination programme for girls aged 12-17 years (cu-
mulative coverage rate at 20 years of 45% and 55% for the 12-14 and 15-17 respec-
tively), alongside current cervical cancer screening, versus screening only.
RESULTS:At a steady state, the model projected that the vaccination strategy could
reduce the number of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1 and
genital wart cases among women by 64.6%, 64.3%, 58.9% and 69.9% respectively. In
addition, girls’ vaccination could indirectly lead to a decrease of 48.2% of genital
warts cases in males. The incremental cost-effectiveness ratio (ICER) of the current
vaccination programme was estimated at €5,525 per QALY and €10,205 per LYG.
Excluding vaccine’s protection against HPV6/11 would increase the ICER to €10,296/
QALY. An increase in girls’ vaccination coverage rates would lead to a substantial
disease reduction. CONCLUSIONS: In Germany, the current quadrivalent HPV vac-
cination programme can be regarded as a cost-effective strategy. An increase in
vaccination coverage rate could lead to a more effective programme. Further public
health benefits could be expected on other HPV-related diseases such as vulvar,
vaginal and anal precancerous lesions on which the quadrivalent vaccine has dem-
onstrated high efficacy.
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OBJECTIVES: There are currently two pneumococcal conjugated vaccines in Ma-
laysia. Pneumococcal vaccination is not currently part of the national immuniza-
tion program (NIP). We studied the cost-effectiveness of population-wide pneumo-
coccal vaccination in Malaysian children with the 13-valent pneumococcal
conjugate vaccine (PCV13) versus the 10-valent pneumococcal conjugate vaccine
(PCV10). METHODS: A 10-year Markov model was used to analyze the population
level public health and economic impact of infant vaccination. Costs were consid-
ered from the payer’s perspective. A 3% discount rate was applied to costs and
outcomes. Local and regional epidemiology data were used when possible. PCV13
and PCV10 effectiveness was extrapolated from PCV7 data, taking into consider-
ation the local serotype distribution. Medical and vaccine costs were obtained from
local sources while lifetime medical costs of disability were estimated from US
data. The analysis assumes a 3-dose vaccination series. Sensitivity analyses were
performed to assess the robustness of the results. RESULTS:More cases of invasive
pneumococcal disease (IPD) (8,671 cases), hospitalized pneumonia (346,716 cases),
non-hospitalized pneumonia (897,729 cases) and acute otitis media (72,220 cases)
are estimated to be avoided following vaccination with PCV13 vs PCV10. 1,952 IPD
related deaths and 16,114 deaths from hospitalized pneumonia would additionally
be prevented. Compared to PCV10, PCV13 saved an additional 489,916 life years and
447,681 QALYs. This resulted in a cost per life-year saved of RM18,011 and a cost per
QALY gained of RM 19,710 for PCV13 vs PCV10. CONCLUSIONS: This analysis sup-
ports the cost-effectiveness of PCV13 vaccination compared with PCV10 in a po-
tential NIP in Malaysia.
PIN47
COST-EFFECTIVENESS OF TELBIVUDINE IN FIRST LINE TREATMENT OF HBEAG-
NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN THE TURKISH
HEALTHCARE SETTING
Pala M1, Sahin U2
1Novartis, Istanbul, Turkey, 2Novartis, istanbul, Turkey
OBJECTIVES: The aim of this study is to analyze the cost-effectiveness over 6-year
duration of first line telbivudine and lamivudine treatment in HBeAg-negative CHB
patients with low viral load at baseline in line with the Turkish reimbursement
guideline for oral CHB therapies. METHODS: Using a decision analytical model,
cost-effectiveness of telbivudine was evaluated versus lamivudine in first-line use
for HBeAg-negative patients with baseline serum HBV DNA levels 7 log10 cop-
ies/mL in Turkish healthcare setting from national payer’s perspective in accor-
dance with the local reimbursement guideline for oral CHB treatments based on
roadmap concept. Primary measure of effectiveness was undetectable HBV DNA
level by polymerase chain reaction (PCR) assay at model duration, while costs
included only cost of oral CHB drugs incurred by the Payer. Probabilities of PCR
negativity and resistance rates used in the model are derived from telbivudine’s
head-to-head study vs lamivudine subgroup analyses outcomes for week 24 and
104; and from respective pivotal clinical studies for second line therapies.
RESULTS: In the CE model, total oral CHB treatment cost per negative patient
treated with lamivudine and telbivudine arm over 6 years was estimated to be
9141€ and 7980€ respectively. Percentage of patients remaining on lamivudine at
model duration was 29%, while 67% on telbivudine. The average cost-effectiveness
ratio, cost per successfully treated patient at year 6, was calculated as 10,754€ for
the lamivudine arm and 8,750€ for the telbivudine arm (difference is 2,004€) and the
incremental cost-effectiveness ratio was -18,726€. CONCLUSIONS: First line CHB
treatment with telbivudine in negative patients has been demonstrated as a dom-
inant cost-effective option than lamivudine in the Turkish health care setting.
Although telbivudine has higher reimbursement price, it has been offset by supe-
rior efficacy compared to lamivudine in HBeAg-negative patients with baseline
serum HBV DNA levels 7 log10 copies/mL and less need for more costly second
line treatments.
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